An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.

Publication Type:

Journal Article


PharmacoEconomics, Volume 26, Issue 4, p.329-39 (2008)


2008, 258, Cardiovascular Diseases, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Models, Economic, Pyrroles, Quality-Adjusted Life Years


The CARDS trial, a multicentre, randomized, controlled trial, found that atorvastatin 10 mg/day for patients with type 2 diabetes mellitus and normal low-density lipoprotein (LDL)-cholesterol significantly reduced cardiovascular (CV) events, including stroke. We estimated the cost effectiveness of atorvastatin as primary prevention against CV disease from the short-term and lifetime US payer perspectives.